Drugs News and Research

RSS

Findings could guide in developing more effective vaccines for HIV/AIDS and cancer

In an acute viral infection, most of the white blood cells known as T cells differentiate into cells that fight the virus and die off in the process. But a few of these "effector" T cells survive and become memory T cells, ensuring that the immune system can respond faster and stronger the next time around.

29 Jan 2010

Study sheds light on pancreatic cancer development and new potential drug targets

Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs. They have shown how a molecular switch steps up pancreatic cancer cell survival as well as resistance to a standard chemotherapy drug, and have identified alternate routes cancer cells take to avoid the effects of the therapy.

29 Jan 2010

Breakthrough in anti-malarial drug development

Malaria causes more than two million deaths each year, but an expert multinational team battling the global spread of drug-resistant parasites has made a breakthrough in the search for better treatment.

29 Jan 2010

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

The treatment of illness has traditionally been based on the law of averages – what works best for the largest number of patients. As a result, billions of dollars are spent every year on treatments that could be ineffective or even harmful for some patients. What if doctors could tell with a simple test which course of treatment would be best for a particular patient?

From QIAGEN Manchester Limited 29 Jan 2010

Researchers discover new target for drugs to prevent common iron deficiency

The discovery of a major player in the body's regulation of iron levels should provide a new target for drugs that prevent common iron deficiency as well as rare, potentially deadly iron overload, researchers said.

29 Jan 2010

New Tel Aviv University study shows early intervention could prevent mind altering disorder

The onset of schizophrenia is not easy to predict. Although it is associated with as many as 14 genes in the human genome, the prior presence of schizophrenia in the family is not enough to determine whether one will succumb to the mind-altering condition. The disease also has a significant environmental link.

29 Jan 2010

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Flexion Therapeutics today announced agreements with four major pharmaceutical partners, acquiring the rights to four clinical-stage compounds, and gaining investment from the world’s biggest pharmaceutical company.

29 Jan 2010

Ecstasy-related death rates in young users is a major public health issue

A paper by a University of Hertfordshire academic due to be published tomorrow (29 January 2010), reports that excess ecstasy-related death rates in young users is a cause for concern.

29 Jan 2010

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

New research in the FASEB Journal shows that bone marrow cells fuse to different types of cells, including embryonic stem cells, creating new hybrids that may evade immune rejection

29 Jan 2010

Level of key immune cells in kidney transplant patients may predict risk of skin cancer

Measuring certain types of immune cells may predict the high risk of skin cancer after kidney transplantation, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

29 Jan 2010

Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor

Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance.

29 Jan 2010

Sports Medicine Clinic offers PRP therapy to heal injured ligaments, tendons and muscles

The Sports Medicine Clinic at the University of Virginia Health System is using a cutting-edge therapy called platelet rich plasma (PRP) to help heal injured ligaments, tendons and muscles.

29 Jan 2010

Increased cost sharing may hurt seniors' health care

Cost sharing and increased co-pays, even if it's just a few dollars, can lead seniors to put off visits to the doctor and result in increased hospital admissions and longer hospital stays, according to a new study.

28 Jan 2010

FDA cautions drug makers about potential abuse

The Los Angeles Times reports that the Food and Drug Administration "this week released a draft of voluntary guidelines to assist drug makers in figuring out which compounds should be placed under the Controlled Substances Act. The law regulates the handling, record-keeping and dispensing of drugs deemed to be dangerous or addictive if misused -- in some cases imposing criminal penalties for misuse.

28 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Aubrey receives FDA clearance to market bioengineered wound dressings in U.S.

Aubrey Inc., an advanced wound care company, announced it has received clearance from the US Food and Drug Administration (FDA) to market the AWBAT Plus product line in the United States.

28 Jan 2010

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Baxter International reports net income of $572M for the fourth-quarter of 2009

Baxter International Inc. today reported strong performance for the fourth quarter of 2009, and provided its financial outlook for the first quarter and full-year 2010.

From Baxter International Inc. 28 Jan 2010

Drugs News and Research

Findings could guide in developing more effective vaccines for HIV/AIDS and cancer

Study sheds light on pancreatic cancer development and new potential drug targets

Breakthrough in anti-malarial drug development

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

Researchers discover new target for drugs to prevent common iron deficiency

New Tel Aviv University study shows early intervention could prevent mind altering disorder

Flexion Therapeutics acquires rights to clinical-stage compounds from four pharmaceutical partners

Ecstasy-related death rates in young users is a major public health issue

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

Level of key immune cells in kidney transplant patients may predict risk of skin cancer

Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor

Sports Medicine Clinic offers PRP therapy to heal injured ligaments, tendons and muscles

Increased cost sharing may hurt seniors' health care

FDA cautions drug makers about potential abuse

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Aubrey receives FDA clearance to market bioengineered wound dressings in U.S.

Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosis

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Celgene reports total revenue of $758M for fourth-quarter of 2009

Baxter International reports net income of $572M for the fourth-quarter of 2009

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News